GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will report financial results for the three and six months ended June 30, 2017 before the market open, and host a conference call at 8:30am Eastern Time on Thursday, August 10th, 2017.
| Conference Call Details | |
| Date: | Thursday, August 10 |
| Time: | 8:30am Eastern Time |
| Domestic: | 888-599-8667 |
| International: | 719-325-4817 |
| Conference ID: | 8401203 |
| Webcast: | http://public.viavid.com/index.php?id=125554 |
| Replays will be available through August 24th: | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 8401203 |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
Altimmune Contacts Bill Enright President and CEO Phone: 240-654-1450 Email: enright@altimmune.com Matthew Duffy Investor Relations Phone: 212-915-0685 Email: matthew@lifesciadvisors.com
